On average, a stage 1 pancreatic cancer progresses to stage 4 in roughly 14 months. That estimate comes from a study published in Gut (a BMJ journal) that compared the average ages of patients diagnosed at each stage and worked backward to calculate how quickly the disease advances. While 14 months is the average, individual cases vary widely depending on the tumor’s biology, genetic mutations, and how aggressively the cancer cells divide.
What the Stages Actually Mean
Stage 1 pancreatic cancer is a tumor still confined to the pancreas, no larger than 4 centimeters across. At stage 1A, it’s 2 cm or smaller. At stage 1B, it’s between 2 and 4 cm. The cancer hasn’t reached nearby blood vessels, lymph nodes, or distant organs.
Stage 4 is defined by metastasis: the cancer has spread to distant sites, most commonly the liver, the lining of the abdominal cavity, the lungs, or the bones. The jump from stage 1 to stage 4 isn’t just about tumor size. It reflects a fundamental shift in the cancer’s behavior, from growing locally to seeding new tumors in other organs.
Why Progression Happens So Fast
Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is unusually aggressive. Tumor doubling times vary enormously between patients. Slow-growing tumors may double in volume every 3.7 years, while fast-growing ones can double in as little as 20 days. That range helps explain why some patients seem to go from early-stage to metastatic disease almost overnight, while others have a longer window before the cancer spreads.
Part of what drives this speed is the genetic makeup of the tumor. Four key mutations tend to accumulate as pancreatic cancer develops. Mutations in two genes (KRAS and CDKN2A) appear early in the cancer’s formation and get things started. Mutations in two others (TP53 and SMAD4) show up later and are associated with more aggressive, advanced disease. The specific combination and severity of these mutations shape how quickly any individual cancer progresses.
How Genetics Influence the Speed
Not all pancreatic cancers carry the same mutations, and the differences matter. Research from Memorial Sloan Kettering found that patients whose tumors had KRAS mutations had a median overall survival of about 39 months after surgery, compared to 91 months for the small number of patients without KRAS mutations. One particular KRAS variant (called G12D) was the most harmful, dropping median survival to around 32 months. KRAS mutations were also specifically linked to liver metastases and larger tumors at diagnosis.
TP53 mutations had a similarly stark effect. Patients with TP53 mutations survived a median of 37 months after surgery versus 65 months without them. Certain severe forms of TP53 mutation more than doubled the three-year recurrence rate: 25.6% with the worst variants compared to 10.4% without. These patients were also far more likely to develop both local and distant recurrences simultaneously, which is exactly the kind of spread that defines stage 4 disease.
In practical terms, a tumor carrying aggressive versions of both KRAS and TP53 mutations will likely progress faster than the 14-month average. A tumor with milder genetic features might progress more slowly, though “slowly” is still relative for a cancer this aggressive.
Why Most Cases Are Caught Late
The 14-month window from stage 1 to stage 4 sounds like it should be enough time to catch the disease. In reality, it rarely is. The pancreas sits deep in the abdomen, behind the stomach, and early-stage tumors there produce few if any noticeable symptoms. By the time most people develop the warning signs that lead to diagnosis (jaundice, unexplained weight loss, new-onset diabetes, persistent back pain), the cancer has often already moved beyond the pancreas.
There is currently no routine screening test for pancreatic cancer in the general population. People with a strong family history or certain inherited genetic syndromes may be offered periodic imaging, but for the vast majority of patients, the disease is found after symptoms appear. Only a small fraction of cases are diagnosed while still localized to the pancreas.
How Stage Affects Survival
The difference between catching pancreatic cancer early and catching it late is dramatic. According to SEER data covering 2016 through 2022, the five-year relative survival rate for localized pancreatic cancer (confined to the pancreas) is 43.6%. That number drops to 17.0% when the cancer has spread to nearby lymph nodes or structures. For stage 4 disease with distant metastases, five-year survival falls to 3.4%.
These numbers have improved in recent years, particularly for localized disease, where survival was much lower just a decade ago. But they underscore why that roughly 14-month progression window matters so much. The gap between a 44% survival rate and a 3% survival rate is the difference between finding the cancer while it’s still contained and finding it after it has spread to the liver or lungs. For the relatively small group of patients diagnosed at stage 1, the outlook is meaningfully better, which is why researchers continue to push for better early detection methods.